Recon: SEC, FTC investigating Aduhelm approval and marketing; Doctors and public health group mount campaign for Biden’s FDA pick

• Biogen says FTC, SEC probing Alzheimer's disease drug (Reuters) (Endpoints) (Fierce)
• In a bid to save Biden’s FDA pick, doctors and public health groups are mounting a rare pressure campaign (STAT)
• Pfizer's COVID cash pile opens opportunities for deals (Reuters)
• Teva, Texas strike opioid settlement worth $225 million (Reuters)
• Breaking with past comments, FDA's Richard Pazdur telegraphs rough road ahead for Lilly's China-developed cancer drug (Endpoints) (STAT)
• Biden’s top science adviser bullied and demeaned subordinates, according to White House investigation (Politico) (WSJ)
• After some lengthy delays, Sanofi gets the FDA's OK for a rare disease drug (Endpoints)
• UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenx (Fierce) (Endpoints)
• Regeneron revenue beats estimates on strong sales of Eylea, COVID therapy (Reuters)
• Pfizer’s $130M Lyme disease vaccine advances to phase 3 after 3^rd shot shown to increase antibodies (Fierce)
• How researchers can get a handle on the monkey shortage for tox studies: FDA explains (Endpoints)

• COVID disrupts health services in over 90% of countries -WHO (Reuters)
• With thousands of jobs on the chopping block, 'nothing's off the table' at Sanofi. What's staying and what's going? (Endpoints)
• France's Sanofi still sees COVID-19 phase 3 trial completed in first quarter (Reuters)
• Innovent/Lilly’s Sintilimab, Developed In China, May Be Headed For Troubled US Waters (The Pink Sheet)
• UK Regulator ‘Optimistic’ About EU Proposals For Northern Ireland Drug Supply (The Pink Sheet)
• CANbridge, targeting gaps in AstraZeneca’s rare disease coverage, posts early-phase data on C5 inhibitor (Fierce)
• UK’s CMA Issues £35m In Fines Over Prochlorperazine (The Pink Sheet)
• India approves Sputnik Light COVID shot for unvaccinated - local manufacturer (Reuters)
• South African regulator approves Sinopharm COVID vaccine (Reuters)
• Approval of COVID vaccine made in South Africa could take 3 years, WHO says (Reuters)
• Nigeria receives 2 million doses of J&J COVID vaccine from EU countries (Reuters)

• Japan PM Kishida calls for doubling booster shots to 1 mln a day (Reuters)
• US coronavirus cases are dropping. Other countries are breaking records. (Washington Post)
• CDC: More vaccinated adults hospitalized with omicron, but fewer admitted to ICU (The Hill)

• GSK finds American missed 37M routine vaccinations amid pandemic (Fierce)
• FDA probes TG Therapeutics’ Ukoniq over potential for elevated death risks 1 year after drug’s approval (Fierce)
• Arcellx raises $124M in Wall Street debut to bankroll study of multiple myeloma CAR-T (Fierce)
• Endeavor snags $101M to go after Boehringer, Roche in lung scarring – and do some asset shopping (Fierce)
• Takeda joins Novartis and Merck in $45M funding for Koneksa Health (Fierce)
• Top 10 most anticipated drug launches of 2022 (Fierce)
• Pharma’s cyber vulnerabilities run deeper than Merck’s ‘NotPetya’ attack: report (Fierce)
• Sanofi ends 2 phase 1 cancer assets weeks after axing Sangamo deal (Fierce)
• Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck’s drug (Fierce)
• Vanda's gastric drug flops in late-stage test, crashing the biotech's stock (Endpoints)
• Vas Narasimhan and Severin Schwan each claimed pay packets worth $12M+ for 2021 (Endpoints)
• Months after Tmunity ground to a halt on clinical hold, cell therapy pioneer Oz Azam is jumping to a stealth startup (Endpoints)

• Ambu scores FDA clearance for single-use gastroscope and touchscreen display (Fierce)
• Roche partner recalls illegally imported rapid COVID-19 tests from US (MedTech Dive)
• Procedure volatility, testing uncertainty & FDA delays: Medtech trends in 2022 (MedTech Dive)

• Philly, Pittsburgh DAs Lose Bid To Stop Opioid Settlement (Law360)
• In a victory for medical journals, Pacira loses a libel lawsuit over ‘faulty scientific research’ allegations (STAT)
• Inside J&J's secret plan to cap litigation payouts to cancer victims (Reuters)
• In upholding Martin Shkreli's lifetime ban, judge rules any statement he makes about pharma could be a violation (Endpoints) (Reuters)